NCT00457275View on ClinicalTrials.gov

Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)

PHASE3CompletedINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Hypercholesterolemia
Interventions
DRUG

MK0653, ezetimibe / Duration of Treatment: 4 Weeks

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00457275 - Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070) | Biotech Hunter | Biotech Hunter